Vertex Pharmaceuticals (VRTX) said Friday it received approval from the UK's Medicines and Healthcare products Regulatory Agency for Alyftrek to treat cystic fibrosis in patients six years and older with at least one F508del or another responsive mutation in the cystic fibrosis transmembrane conductance regulator gene.
Alyftrek is a triple combination cystic fibrosis transmembrane conductance regulator modulator treatment, the company added.
The US Food and Drug Administration approved Alyftrek in December 2024.
Price: 488.10, Change: +2.38, Percent Change: +0.49
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.